VJHemOnc is committed to improving our service to you

ESH AL 2020 | Itacitinib in patients with acute GvHD

VJHemOnc is committed to improving our service to you

John DiPersio

John DiPersio, MD, PhD, Washington University School of Medicine, Washington, WA, discusses a Phase I trial (NCT02614612) of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease (GvHD). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter